Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00667992 · ClinicalTrials.gov registry record · Phase 3
Study Comparing Budesonide Hydrofluoroalkane (HFA) vs Chlorofluorocarbon (CFC) Pressurized Metered Dose Inhalers (pMDI) in Patients With Mild to Moderate Asthma
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 99
- Enrollment target
NCT00667992 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 99 participants.
The verdict
NCT00667992, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 99 participants
- Enrollment target
Study Summary
This study is being carried out to see if budesonide with HFA is effective, safe and well tolerated compared with budesonide CFC. Budesonide HFA has been already given in other research studies, in both healthy volunteers and subjects with asthma.
Interventions
- DRUG Budesonide HFA
- DRUG Budesonide CFC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2008-04 |
| Est. Completion | 2009-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00667992
The ClinicalTrials.gov registry entry for NCT00667992 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Budesonide HFA is the first listed.
NCT00667992 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00667992 about?
NCT00667992 is a clinical study titled "Study Comparing Budesonide Hydrofluoroalkane (HFA) vs Chlorofluorocarbon (CFC) Pressurized Metered Dose Inhalers (pMDI) in Patients With Mild to Moderate Asthma". This study is being carried out to see if budesonide with HFA is effective, safe and well tolerated compared with budesonide CFC. Budesonide HFA has been already given in other research studies, in both healthy volunteers and subjects with asthma.
What is the current status of trial NCT00667992?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 99 participants. The study started on 2008-04. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00667992?
The interventions under investigation include: Budesonide HFA (DRUG), Budesonide CFC (DRUG).
Who is sponsoring clinical trial NCT00667992?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.